Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

被引：0
|
作者：
Guarino, Michael J.
Starodub, Alexander
Masters, Gregory A.
Heist, Rebecca Suk
Messersmith, Wells A.
Bardia, Aditya
Ocean, Allyson J.
Thomas, Sajeve Samuel
Maliakal, Pius P.
Wegener, William A.
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
机构：
[1] Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA
[2] Indiana Univ Hlth, Goshen Ctr Canc Care, Goshen, IN USA
[3] Helen F Graham Canc Ctr, Newark, DE USA
[4] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[5] Univ Colorado Canc Ctr, Aurora, CO USA
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
[7] Weill Cornell Med Coll, New York, NY USA
[8] Univ Florida, Windermere, FL USA
[9] Immunomedics Inc, Morris Plains, NJ USA
[10] Garden State Canc Ctr, Ctr Mol Med & Immunol, Morris Plains, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.2504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2504
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer
    Weiten, Richard
    Niemann, Max
    Below, Eduard
    Friker, Lea L.
    Ralser, Damian J.
    Toma, Marieta
    Kristiansen, Glen
    Hahn, Oliver
    Zechel, Sabrina
    Gruenwald, Viktor
    Bald, Tobias
    Siewert, Johannes
    Pietsch, Torsten
    Ritter, Manuel
    Hoelzel, Michael
    Eckstein, Markus
    Alajati, Abdullah
    Krausewitz, Philipp
    Kluemper, Niklas
    CANCER MEDICINE, 2024, 13 (12):
  • [42] Preclinical evidence for the use of anti-TROP-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer
    Weiten, R.
    Niemann, M.
    Below, E.
    Friker, L. L.
    Ralser, D. J.
    Toma, M.
    Kristiansen, G.
    Hahn, O.
    Zechel, S.
    Gruenwald, V.
    Bald, T.
    Siewert, J.
    Pietsch, T.
    Ritter, M.
    Hoelzel, M.
    Eckstein, M.
    Alajati, A.
    Krausewitz, P.
    Kluemper, N.
    EUROPEAN UROLOGY, 2024, 85 : S1430 - S1431
  • [43] First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
    Starodub, Alexander N.
    Ocean, Allyson J.
    Shah, Manish A.
    Guarino, Michael J.
    Picozzi, Vincent J., Jr.
    Vahdat, Linda T.
    Thomas, Sajeve S.
    Govindan, Serengulam V.
    Maliakal, Pius P.
    Wegener, William A.
    Hamburger, Steven A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3870 - 3878
  • [44] Initial results of a new antibody-drug conjugate (ADC), IMMU-130 (labetuzumab-SN38), in patients with metastatic colorectal cancer (mCRC)
    Segal, N. H.
    Verghis, J.
    Govindan, S.
    Maliakal, P.
    Sharkey, R. M.
    Wegener, W. A.
    Goldenberg, D. M.
    Saltz, L. B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S545 - S546
  • [45] Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer
    Bardia, A.
    Spring, L. M.
    Juric, D.
    Partridge, A.
    Ligibel, J.
    Kuter, I.
    Peppercorn, J.
    Parsons, H.
    Ryan, P.
    Chawla, D.
    Attaya, V.
    Fitzgerald, D. M.
    Viscosi, E.
    Lormill, B.
    Shellock, M.
    Moy, B.
    Tolaney, S. M.
    Ellisen, L. W.
    ANNALS OF ONCOLOGY, 2020, 31 : S394 - S394
  • [46] IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies
    Segal, Neil H.
    Dotan, Efrat
    Berlin, Jordan D.
    Starodub, Alexander N.
    Guarino, Michael J.
    Saltz, Leonard B.
    Maliakal, Pius P.
    Govindan, Serengulam V.
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2014, 74 (19)
  • [47] Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
    Perrone, Emanuele
    Lopez, Salvatore
    Zeybek, Burak
    Bellone, Stefania
    Bonazzoli, Elena
    Pelligra, Silvia
    Zammataro, Luca
    Manzano, Aranzazu
    Manara, Paola
    Bianchi, Anna
    Buza, Natalia
    Tymon-Rosario, Joan
    Altwerger, Gary
    Han, Chanhee
    Menderes, Gulden
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Hui, Pei
    Schwartz, Peter E.
    Scambia, Giovanni
    Santin, Alessandro D.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [48] Activity of IMMU-130 anti-CEACAM5-SN-38 antibody-drug conjugate (ADC) on metastatic colorectal cancer (mCRC) having relapsed after CPT-11: Phase I study.
    Dotan, Efrat
    Berlin, Jordan
    Starodub, Alexander
    Guarino, Michael J.
    Cohen, Steven J.
    Maliakal, Pius P.
    Govindan, Serengulam V.
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] PHARMACOKINETICS (PK) OF SACITUZUMAB GOVITECAN (SG), A TROP-2-DIRECTED ANTIBODY-TOPOISOMERASE I INHIBITOR SN-38 DRUG-CONJUGATE, IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS.
    Singh, I.
    Sathe, A.
    Singh, P.
    Boakye-Agyeman, F.
    Tatalick, L.
    Goswami, T.
    Girish, S.
    Othman, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S48 - S48
  • [50] IMMU-130, a unique antibody-drug conjugate (ADC) of SN-38 targeting CEACAM5 antigen: Preclinical basis for clinical activity in metastatic colorectal cancer (mCRC).
    Govindan, Serengulam V.
    Cardillo, Thomas M.
    Rossi, Edmund A.
    McBride, William J.
    Sharkey, Robert M.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345